Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Holdings in Biogen Inc. $BIIB

Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in Biogen Inc. (NASDAQ:BIIB) by 16.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,736 shares of the biotechnology company’s stock after selling 23,908 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Biogen were worth $21,834,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Accredited Wealth Management LLC lifted its holdings in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp acquired a new position in Biogen during the 4th quarter worth $30,000. WFA of San Diego LLC acquired a new position in Biogen during the 2nd quarter worth $32,000. True Wealth Design LLC lifted its holdings in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares in the last quarter. Finally, GoalVest Advisory LLC acquired a new position in Biogen during the 4th quarter worth $35,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Biogen Stock Performance

BIIB stock opened at $184.38 on Friday. The business’s fifty day moving average is $185.13 and its 200-day moving average is $175.03. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a market cap of $27.06 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.16. Biogen Inc. has a twelve month low of $115.25 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts forecast that Biogen Inc. will post 15.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BIIB. JPMorgan Chase & Co. upped their price objective on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Biogen in a report on Monday, February 9th. Wedbush upped their price objective on Biogen from $187.00 to $191.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. BMO Capital Markets upped their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Finally, Guggenheim upped their price objective on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $211.31.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.